HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bok Lee, H. Articles by Blaufox, M. D. Search for Related Content PubMed PubMed Citation Articles by Bok Lee, H. Articles by Blaufox, M. D.

In Vivo Detection of Deposition of Radiolabeled Lupus Antikidney Antibody and Its Inhibition by Soluble Antigen

Department of Nuclear Medicine and Department of Microbiology and Immunology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York

This investigation in an animal model was designed to test the feasibility of using radiolabeled lupus antikidney antibody to show renal deposition in vivo and the ability to block this deposition with a binding peptide. Methods: BALB/c mice received injections of radiolabeled murine anti-DNA antibody, antibody with no DNA binding capability, and DNA antibody simultaneously with blocking peptide. Results: Significantly higher renal deposition of anti-DNA antibody than of antibody without DNA binding capability occurred in the animals at 48 h after injection (5.21% of the injected dose per gram of tissue versus 2.5%, P < 0.0004) and at 7–8 d after injection (1.44% versus 0.20%, P < 0.00004). The simultaneous injection of blocking peptide with anti-DNA binding antibody significantly reduced the renal deposition of the anti-DNA antibody at 48 h (1.53%, P < 0.00001) and at 7–8 d (0.64%, P < 0.0017). Conclusion: This study showed the feasibility of using a radiolabeled antibody to evaluate deposition of anti-DNA antibody in the kidney and the successful use of a peptide to block antibody deposition—a strategy that may be useful for renal preservation in lupus. These data support the possibility of using antikidney-labeled antibodies to evaluate immunologic renal disease in vivo in humans.

Key Words: systemic lupus erythematosus • radiolabeled anti-DNA antibody • anti-DNA antibody–blocking peptide • immunologic renal disease

This article has been cited by other articles:

				M. Blank and Y. Shoenfeld Experimental models of systemic lupus erythematosus: anti-dsDNA in murine lupus Rheumatology, September 1, 2005; 44(9): 1086 - 1089. [Full Text] [PDF]